Validation of the Kazakh version of the movement disorder Society-Unified Parkinsons disease rating scale
Abdraimova S. Myrzayev Z. Karimova A. Talgatkyzy A. Khaibullin T. Kaishibayeva G. Elubaeva S. Esembekova K. Choi D. Martinez-Martin P. Goetz C.G. Stebbins G.T. Luo S. Shashkin C. Zharkinbekova N. Kaiyrzhanov R.
January 2024Elsevier Ltd
Clinical Parkinsonism and Related Disorders
2024#10
Background and Purpose: The International Movement Disorder Society revision of the Unified Parkinsons Disease Rating Scale (MDS-UPDRS) is widely used in the assessment of the severity of Parkinsons disease (PD). This study aimed to validate the Kazakh version of the MDS-UPDRS, explore its dimensionality, and compare it to the original English version. Methods: The validation was conducted in three phases: first, the English version of the MDS-UPDRS was translated into Kazakh and thereafter back-translated into English by two independent teams; second, the Kazakh version underwent a cognitive pretesting; third, the Kazakh version was tested in 360 native Kazakh-speaking PD patients. Both confirmatory and exploratory factor analyses were performed to validate the scale. We calculated the comparative fit index (CFI) for confirmatory factor analysis and used unweighted least squares for exploratory factor analysis. Results: The CFI was higher than 0.90 for all parts of the scale, thereby meeting the pre-set threshold for the official designation of a validated translation. Exploratory factor analysis also showed that the Kazakh MDS-UPDRS has the analogous factors structure in each part as the English version. Conclusions: The Kazakh MDS-UPDRS had a consistent overall structure as the English MDS-UPDRS, and it was designated as the official Kazakh MDS-UPDRS, which can reliably be used in the Kazakh-speaking populations. Presently, Kazakhstan stands as the sole country in both Central Asia and Transcaucasia with an MDS-approved translated version of the MDS-UPDRS. We expect that other Central Asian and Transcaucasian countries will embark on the MDS Translation Program for MDS-UPDRS in the near future.
MDS-UPDRS , Parkinsons Disease , Rating scale , Validation
Text of the article Перейти на текст статьи
South Kazakhstan Medical Academy, Department of Neurology, Psychiatry, Rehabilitology and Neurosurgery, Shymkent, Kazakhstan
International Research Institute of Postgraduate Education, Department of Neurosurgery and Neurology, Almaty, Kazakhstan
Kazakh National University n.a. Al-Farabi, Department of Biomedicine, Biophysics and Neuroscience, Almaty, Kazakhstan
“Semey Medical University”, Department of Neurology, Ophthalmology, and Otorhinolaryngology, Semey, Kazakhstan
Institute of Neurology and Neurorehabilitation n.a. Smagul Kaishibayev, Almaty, Kazakhstan
Nazarbayev University, Graduate School of Education (NU GSE), Educational Leadership (School Education), Astana, Kazakhstan
Nazarbayev Intellectual School of Physics and Mathematics, Semey, Kazakhstan
Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States
Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States
Institute of Neurology, University College London, Department of Neuromuscular Disorders, Queen Square, London, United Kingdom
South Kazakhstan Medical Academy
International Research Institute of Postgraduate Education
Kazakh National University n.a. Al-Farabi
“Semey Medical University”
Institute of Neurology and Neurorehabilitation n.a. Smagul Kaishibayev
Nazarbayev University
Nazarbayev Intellectual School of Physics and Mathematics
Department of Biostatistics and Bioinformatics
Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED)
Department of Neurological Sciences
Institute of Neurology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026